+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Activity and safety of L-700462, a selective GPIIb/IIIa antagonist, in healthy volunteers



Activity and safety of L-700462, a selective GPIIb/IIIa antagonist, in healthy volunteers



Circulation 86(4 Suppl. 1): I866




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 029882408

Download citation: RISBibTeXText


Related references

Pharmacokinetics, pharmacodynamics, and safety of a platelet GPIIb/IIIa antagonist, RGD891, following intravenous administration in healthy male volunteers. Journal of Clinical Pharmacology 40(11): 1245-1256, 2000

Pharmacodynamics of the GPIIb-IIIa antagonist integrelin Phase I clinical studies in normal healthy volunteers. Circulation 86(4 Suppl. 1): I260, 1992

Safety, pharmacokinetics and dynamics of the oral GPIIb/IIIa inhibitor lefradafiban in healthy volunteers. Circulation 96(8 Suppl. ): I721, 10/21/97, 1997

Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes. Blood 98(12): 3256-3260, 2001

Pharmacokinetic and pharmacodynamic analysis of TS-943, a selective non-peptide platelet glycoprotein-IIb/IIIa (GPIIb/IIIa) receptor antagonist, using a nonlinear mixed effect model in dogs. Journal of Pharmacy and Pharmacology 54(7): 921-927, 2002

Comparison of YM-60828, a newly synthesized factor Xa inhibitor, and SC-54701A, a selective GPIIb/IIIa antagonist Antithrombotic activity in three thrombosis models in guinea pigs. Japanese Journal of Pharmacology 79(Suppl. 1): 183P, 1998

FK633 A potent and selective platelet GPIIb/IIIa antagonist. Cardiovascular Drug Reviews 17(2): 147-159, Summer, 1999

Pharmacodynamics and pharmacokinetics of DMP 728, a platelet GPIIb/IIIa antagonist, in healthy subjects. Clinical Pharmacology and Therapeutics 63(3): 384-392, 1998

Safety, tolerability, pharmacokinetics, and time course of pharmacologic response of the active metabolite of roxifiban, XV459, a glycoprotein IIb/IIIa antagonist, following oral administration in healthy volunteers. Journal of Clinical Pharmacology 42(7): 738-753, 2002

Antiplatelet efficacy and safety of the platelet GPIIb/IIIa antagonist, DMP 728 in anesthetized dogs. Circulation 88(4 Part 2): I319, 1993

Highly selective cyclic hexapeptides antagonist of GPIIb-IIIa by multiple N-methylation. Advances in Experimental Medicine and Biology 611: 209-210, 2009

Inhibitory effects by the combination quinapril, a tissue selective angiotensin converting enzyme inhibitor, and G4120, a non-selective GPIIb/IIIa antagonist, on neointima formation in hamsters. Japanese Journal of Pharmacology 71(Suppl. 1): 316P, 1996

Intravenous antiplatelet efficacy and safety of the platelet GPIIb/IIIa antagonist, DMP 728 in anesthetized dogs. Thrombosis Research. 76(2): 109-119, 1994

Integrated pharmacokinetic/pharmacodynamic model of XV459, a potent and specific GPIIb/IIIa inhibitor, in healthy male volunteers. Journal of Clinical Pharmacology 42(12): 1326-1334, 2002